Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.41 |
| ▸ | GRB2 | P62993 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29522093 | 0.85 | PTPN1 (0.40) | PTPN1HDAC1HDAC2 | |
| SCHEMBL30518584 | 0.76 | PTPN1 (0.45) | PTPN1GRB2 | |
| SCHEMBL31614333 | 0.76 | MDM2 (0.53) | MDM4TP53 | |
| SCHEMBL29400571 | 0.76 | MDM2 (0.53) | MDM4TP53 | |
| SCHEMBL12527832 | 0.76 | MDM2 (0.53) | MDM4TP53 | |
| SCHEMBL31212511 | 0.76 | MDM2 (0.50) | PTPN1MDM4TP53 | |
| SCHEMBL16435194 | 0.76 | MDM2 (0.50) | PTPN1MDM4TP53 | |
| SCHEMBL17729113 | 0.75 | CASP3 (0.40) | PTPN1 | |
| SCHEMBL29684642 | 0.75 | CASP3 (0.40) | PTPN1 | |
| SCHEMBL31681574 | 0.74 | MDM2 (0.45) | MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580754-A1 | AN INTEGRIN ALPHA10 ANTIBODY DRUG CONJUGATE | Targinta AB (SE) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024047172-A1 | AN INTEGRIN ALPHA10 ANTIBODY DRUG CONJUGATE | TARGINTA AB (SE) | 2024-03-07 | — | — | WO | disclosed |
| US-20230398232-A1 | Composition and Use of Alternatively Formatted Anti-Mesothelin Antibodies for the Treatment of Cancer | Navrogen, Inc. | 2023-12-14 | — | — | US | disclosed |
| EP-4217009-A1 | COMPOSITION AND USE OF ALTERNATIVELY FORMATTED ANTI-MESOTHELIN ANTIBODIES FOR THE TREATMENT OF CANCER | Navrogen, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022067224-A1 | COMPOSITION AND USE OF ALTERNATIVELY FORMATTED ANTI-MESOTHELIN ANTIBODIES FOR THE TREATMENT OF CANCER | Navrogen, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |